Nymox Wins Legal Battles in US and Bahamas
Ticker: NYMXF · Form: 6-K · Filed: Sep 23, 2025 · CIK: 1018735
| Field | Detail |
|---|---|
| Company | Nymox Pharmaceutical CORP (NYMXF) |
| Form Type | 6-K |
| Filed Date | Sep 23, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | mixed |
Sentiment: mixed
Topics: legal-victory, litigation, bahamas
TL;DR
Nymox wins lawsuit dismissal in California, Bahamas case heads to final hearing.
AI Summary
Nymox Pharmaceutical Corporation announced on September 23, 2025, that the U.S. District Court for the Central District of California dismissed Randall Lanham's complaint against the company and Computershare Investor Services Inc. with prejudice. Additionally, the Registrar for the Supreme Court of the Bahamas held a final hearing regarding a case brought by Mr. Lanham, Mr. Riley, CRNSV, and others.
Why It Matters
The dismissal of the lawsuit in the U.S. and the final hearing in the Bahamas are positive developments that reduce legal uncertainty for Nymox Pharmaceutical Corporation.
Risk Assessment
Risk Level: medium — While the dismissal in the US is positive, the ongoing legal proceedings in the Bahamas introduce continued uncertainty.
Key Players & Entities
- Nymox Pharmaceutical Corporation (company) — Registrant
- Computershare Investor Services Inc. (company) — Co-defendant in US lawsuit
- Randall Lanham (person) — Plaintiff in US lawsuit and Bahamas case
- Mr. Riley (person) — Plaintiff in Bahamas case
- CRNSV (company) — Plaintiff in Bahamas case
- U.S. District Court for the Central District of California (company) — Court that dismissed US lawsuit
- Supreme Court of the Bahamas (company) — Court holding final hearing in Bahamas case
FAQ
What was the outcome of Randall Lanham's complaint in the U.S. District Court for the Central District of California?
The U.S. District Court for the Central District of California granted Nymox Pharmaceutical Corporation's and Computershare Investor Services Inc.'s motion to dismiss Randall Lanham's complaint, dismissing the case with prejudice.
What is the status of the case brought by Mr. Lanham, Mr. Riley, CRNSV, and others in the Bahamas?
The Registrar for the Supreme Court of the Bahamas held a final hearing in the case brought by Mr. Lanham, Mr. Riley, CRNSV, and others.
Which court dismissed the complaint filed by Randall Lanham?
The U.S. District Court for the Central District of California dismissed the complaint.
Who were the parties involved in the dismissed U.S. lawsuit?
The parties involved were Nymox Pharmaceutical Corporation, Computershare Investor Services Inc., and Randall Lanham.
What is Nymox Pharmaceutical Corporation's principal executive office address?
Nymox Pharmaceutical Corporation's principal executive office is located at Bay & Deveaux Streets, Nassau, The Bahamas.
Filing Stats: 236 words · 1 min read · ~1 pages · Grade level 10.8 · Accepted 2025-09-23 14:53:05
Filing Documents
- nymox_6k.htm (6-K) — 8KB
- nymox_6kimg1.jpg (GRAPHIC) — 3KB
- 0001640334-25-001701.txt ( ) — 13KB
From the Filing
nymox_6k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September, 2025 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation (Translation of registrant's name into English) Bay & Deveaux Streets, Nassau, The Bahamas (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Nymox Pharmaceutical Corporation (the "Company") reports that the U.S. District for the Central District of California granted the Company's and Computershare Investor Services Inc.'s motion to dismiss Randall Lanham's complaint, and dismissed the case, with prejudice. The Company also reports that the Registrar for the Supreme Court of Bahamas held a final hearing in the case brought by Mr. Lanham, Mr. Riley, CRNSV, and others, which was withdrawn. The Registrar awarded costs to the Company, the details of which will be reported once the Bahama's Court issues its final Order. The Company expects the final Order to be issued soon. 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 22, 2025 NYMOX PHARMACEUTfCAL CORPORATION By: Name: Paul Averback Title: President and Chief Executive Officer 3